1	A randomized double-blind placebo-controlled trial of Guanfacine Extended Release for
2	aggression and self-injurious behavior associated with Prader-Willi Syndrome
3	
4	
5	Deepan Singh <sup>1*</sup> , Michael Silver <sup>2</sup> , Theresa Jacob <sup>1, 3</sup>
6	
7	
8	<sup>1</sup> Department of Psychiatry, Maimonides Medical Center, Brooklyn, New York
9	<sup>2</sup> Research Administration, Maimonides Medical Center, Brooklyn, New York
10	<sup>3</sup> Clinical and Translational Research Labs, Maimonides Medical Center, Brooklyn, New York
11	
12	
13	* Corresponding Author
14	Email: <u>desingh@maimo.org</u> (DS)
15	
16	
17	Short title:
18	Guanfacine XR Against Behavioral Problems in PWS
19	

## 20 Abstract

Introduction: Prader-Willi Syndrome (PWS), a rare genetic disorder, affects development and behavior, frequently resulting in self-injury, aggression, hyperphagia, oppositional behavior, impulsivity and over-activity causing significant morbidity. Currently, limited therapeutic options are available to manage these neuropsychiatric manifestations. The aim of this clinical trial was to assess the efficacy of guanfacine-extended release (GXR) in reducing aggression and self-injury in individuals with PWS.

Trial Design: Randomized, double-blind, placebo-controlled trial conducted under IRB approval.
Methods: Subjects with a diagnosis of PWS, 6-35 years of age, with moderate to severe aggressive
and/or self-injurious behavior as determined by the Clinical Global Impression (CGI)-Severity
scale, were included in an 8-week double-blind, placebo-controlled, fixed-flexible dose clinical
trial of GXR, that was followed by an 8-week open-label extension phase. Validated behavioral
instruments and physician assessments measured the efficacy of GXR treatment, its safety and
tolerability.

**Results:** GXR was effective in reducing aggression/agitation and hyperactivity/noncompliance as 34 measured by the Aberrant Behavior Checklist (ABC) scales (p=0.03). Overall aberrant behavior 35 scores significantly reduced in the GXR arm. Aggression as measured by the Modified Overt 36 Aggression Scale (MOAS) also showed a significant reduction. Skin-picking lesions as measured 37 by the Self Injury Trauma (SIT) scale decreased in response to GXR. No serious adverse events 38 were experienced by any of the study participants. Fatigue /sedation was the only adverse event 39 40 significantly associated with GXR. The GXR group demonstrated significant overall clinical improvement as measured by the CGI-Improvement (CGI-I) scale. (p<0.01). 41

42 Conclusion: Findings of this pragmatic trial strongly support the use of GXR for treatment of
43 aggression, skin picking, and hyperactivity in children, adolescents, and adults with PWS.

44

#### 45 **Trial Registration**

46 ClinicalTrials.gov Identifier: <u>NCT05657860</u>

47

48

## 49 Introduction

Prader-Willi syndrome (PWS) is a rare, complex multisystem genetic disorder, which 50 includes hypothalamic dysfunction, cognitive and behavioral problems, increased anxiety, and 51 compulsive behaviors.<sup>1,2</sup> It is the most common genetic cause of morbid obesity in children.<sup>2</sup> 52 While hyperphagia is seen as the sine qua non of PWS, other behavioral symptoms such as 53 aggression, oppositional behavior, and temper tantrums, are common and cause significant distress 54 to patients and caregivers. <sup>3, 4, 5</sup> PWS also has a high prevalence of self-injurious behavior such 55 as skin-picking, as well as repetitive motor activity, impulsivity, and hyperactivity.<sup>6, 7, 8, 9</sup> Despite 56 the high prevalence of behavioral disturbances in PWS, evidence-based pharmacological treatment 57 options for them remain limited. <sup>10</sup> In fact, at the time of this writing, there are no published results 58 from any randomized controlled clinical trials evaluating the efficacy of any agent against the 59 common behavioral disturbances seen in PWS except for hyperphagia. This is particularly 60 61 concerning given that close to half of all children between ages 11-17 and over 65% of all adults

with PWS are on at least one prescribed psychotropic medication with most of them requiring
 more than one medication.<sup>11</sup>

Currently, serotonin reuptake inhibitors (SRIs) and atypical antipsychotics are the most 64 frequently utilized medications to manage behavioral problems in PWS.<sup>11</sup> Both these classes of 65 medications are associated with the potential for developing or worsening metabolic syndrome. <sup>12,</sup> 66 <sup>13, 14, 15</sup> Due to the high risk of obesity in PWS, it is important to avoid weight gain-inducing 67 agents as much as possible. Furthermore, there have been reports of the development of psychotic 68 symptoms such as auditory/visual hallucinations and paranoid delusions with the use of SRIs and 69 serotonin-agonists, making serotonergic agents potentially dangerous in this population.<sup>16, 17</sup> 70 Impulsivity and hyperactivity are well-known presenting signs of attention-deficit/hyperactivity 71 disorder (ADHD), and as many as 25% of the patients with PWS exhibit these symptoms.<sup>7</sup> 72 73 Stimulants for the management of impulsivity and hyperactivity may sometimes worsen mood, and irritability, and chronic use of stimulants may lead to an increase in skin-picking behavior.<sup>18</sup> 74 Although N-acetyl cysteine and oxytocin have been suggested for the management of skin-picking 75 behaviors, safe and effective modalities remain sparse for the management of behavioral 76 symptoms in PWS. 19, 20, 21, 1 77

Guanfacine extended-release (GXR) is a postsynaptic  $\alpha$ 2-adrenoceptor agonist approved by the Food and Drug Administration (FDA) for the management of ADHD. <sup>22, 23</sup> Guanfacine is proposed to work by moderating the activity of the left dorsolateral prefrontal cortex associated with the emotional biasing of response execution, thus reducing impulsivity. <sup>24</sup> Medications that operate as  $\alpha$ 2-adrenoceptor agonists such as guanfacine are beneficial in treating disruptive and aggressive behaviors. <sup>25</sup> In addition, GXR has been demonstrated to be safe and effective for reducing hyperactivity, impulsivity, and distractibility in patients with autism. <sup>26, 27</sup> Most

85	importantly, GXR has had no reports of significant weight gain, worsening hyperphagia, or other
86	metabolic side effects. <sup>28, 29</sup> A retrospective cohort study has demonstrated that GXR led to
87	improvement in symptoms of skin picking, aggression/agitation, and ADHD in patients with PWS.
88	$^{30}$ Given the significant morbidity caused by these behavioral problems in this already vulnerable
89	population, novel evidence-based approaches are warranted for the management of aggression,
90	impulsivity, and self-injury in PWS. <sup>31</sup> It was postulated that GXR is a safer treatment option for
91	self-injurious and aggressive behaviors in PWS and we wanted to test this with a pragmatic
92	approach.

The objective of this randomized, double-blind, placebo-controlled trial was to determine the efficacy of guanfacine extended release (GXR) in reducing aggression and self-injury in individuals with PWS, and to assess its safety and tolerability.

96

97

# 98 Methods

#### 99 Study Design

This pragmatic two-phase 16-week study was designed to test the hypothesis that GXR is effective in reducing aggression and self-injury in individuals with PWS with moderate to severe aggressive and/or self-injurious behavior. In the first phase, the randomized controlled trial part, eligible subjects were randomly assigned in a 1:1 ratio, without stratification, to GXR or placebo for 8 weeks. This was the double-blind, placebo-controlled, fixed-flexible dose phase of the

clinical trial. Immediately following the blinded randomized trial period, an 8-week open-label
extension was pursued to further define the efficacy and tolerability of GXR, as well as to establish
its safety with a specific focus on metabolic profile.

The study was performed in accordance with all current applicable regulations, the 108 International Conference on Harmonization of Good Clinical Practice, the principles of the 109 Declaration of Helsinki and local ethical and legal requirements. It was approved by the 110 Institutional Review Board (# 2020-11-03-MMC) and registered at ClinicalTrials.gov (identifier: 111 NCT05657860). It was conducted in a mental health clinic setting of a large, urban, community-112 based teaching hospital in a major metropolis of the United States. The study recruitment period 113 began March 1, 2021 and ended October 31, 2023. Study participants received complete 114 115 information regarding the protocol during the consent process before enrollment. Written, IRBapproved informed consent was obtained from each participant's parent or legal guardian, and 116 assent was obtained from each participant, as applicable. 117

#### 118 Inclusion/Exclusion Criteria

To be eligible for inclusion, subjects had to be between 6 and 35 years of age with a 119 diagnosis of PWS confirmed by genetic testing. In addition, a rating of moderate or above on the 120 121 Clinical Global Impression - Severity scale (CGI-S) was required for inclusion. Females of childbearing potential had to have a negative urine pregnancy test at screening and baseline and to 122 comply with any protocol contraceptive requirements. In addition, participants and their 123 124 parent/legal guardian had to be willing, able, and likely to fully comply with the study procedures and restrictions defined in the protocol. Exclusionary criteria included a positive pregnancy test, 125 swallowing difficulty, or the presence of clinically significant bradycardia or hypotension. Those 126

currently on GXR, actively enrolled in other studies, or with a lactose intolerance or allergy were 127 also excluded. Subjects receiving antipsychotic medications due to a documented history of 128 psychosis or bipolar disorder were allowed to continue taking the medication without dosage 129 modification. The pragmatic approach of this trial also allowed growth hormone, thyroid hormone 130 replacement treatment, and non-psychiatric medicines, to continue albeit without dosage 131 modifications. Similarly, N-Acetyl Cysteine (NAC) and anticonvulsant medications if prescribed 132 for seizures were allowed, with specific instructions to refrain from making any dosage changes 133 during the trial period. 134

#### 135 Study Drug Administration

The starting dose for all subjects was 1 mg per day. Subjects weighing less than 25 kg 136 remained on the 1 mg dose until day 14. If the medication was well tolerated, the dose was raised 137 to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. Subjects weighing 138 25 kg or more were eligible for an increase to 2 mg at day 7, 3 mg at day 14, and 4 mg at day 21 139 or day 28. The dose schedule was not fixed; the treating clinician could delay a planned increase 140 141 or lower the dose to manage adverse effects. Medication was dispensed at the baseline visit and at the unblinding visit for the subsequent dosing period. GXR was administered as 1 mg capsules; 142 placebo group received matching placebo capsules. 143

# 144 Randomization and Blinding

Subjects were randomly assigned to either the placebo or experimental (GXR) group in a 1:1 ratio via a computer-generated randomization scheme with randomly permuted blocks of varying sizes, done by Pharmacy. As the first phase of this study was double-blinded, the study

pharmacist was the only team member aware of patient treatment assignments. Randomization
occurred at baseline (visit 1). Unblinding was at week 8, and subjects continued treatment for 8
more weeks (open-label phase).

#### 151 Assessments

Baseline and follow-up assessments included the Aberrant Behavior Checklist, (ABC), Self-Injury Trauma (SIT) scale, physician-administered Clinical Global Impression – Severity (CGI-S; only at baseline), and CGI-Improvement (CGI-I) scales, Hyperphagia Questionnaire for use in PWS clinical trials (HQ-CT), Modified Overt Aggression Scale (MOAS), and the Epworth Sleepiness Scale (ESS) at biweekly study visits. The ABC includes an overall score and sub-scores to monitor irritability, lethargy, inappropriate speech, hyperactivity and stereotypies.

In addition, laboratory tests, medical and psychiatric histories, physical examination, electrocardiography (ECG), and vital signs evaluation were conducted at study visits. Daily monitoring of vitals and problematic behavior was performed by caregivers.

#### 161 Safety Monitoring

Blood pressure and pulse rate were measured at each visit. Laboratory tests were conducted at baseline and were repeated at week 8 and week 16. An ECG was obtained at baseline and at week 8 to assess the impact of GXR on cardiac conduction. Adverse events were systematically reviewed and documented. Side effects were measured using open-ended clinician inquiry with questions about drowsiness, fatigue, decreased appetite, emotional/tearful, dry mouth, irritability, anxiety, headache, increased energy, mid-sleep wakening, stomachache, constipation, increased repetitive behavior, aggression, depressed mood, cough/congestion, self-injury, nausea, trouble
falling asleep, dizziness, silly, weakness, diarrhea, vomiting, increased appetite, excessive talking,
blurred vision, skin rash/eczema, nightmares, enuresis, motor tics, skin-picking, and pyrexia.

171 Subjects who were randomly assigned to placebo group and did not show a positive 172 response by 8 weeks, were offered open-label treatment with GXR for 8 weeks. All subjects in 173 this continuation phase were seen every 2 weeks for monitoring. Those unblinded and started on 174 GXR were monitored weekly for the first 4 weeks of the continuation phase.

#### 175 Data Analysis

Data were analyzed using an intent-to-treat approach. Patient baseline data were 176 177 summarized via descriptive statistics such that continuous variables were summarized by means 178 (SD) or medians (IQR) and categorical data by counts (%). Baseline factors (CGI-S, age, gender) 179 as well as all study observations were presented within each group. In the analysis, distributions 180 were compared between treatment groups at baseline via the Wilcoxon rank sum test. Finally, we 181 created a repeated measures linear regression model for each outcome scale, using Generalized Estimating Equations (GEE) to account for within-subject variability, with the predictor of 182 183 treatment, to assess the impact of treatment across the entire timeline of the study. An unstructured correlation matrix was assumed. All models were then plotted in a Forest Plot for ease of 184 comparison. Two-sided p-values < 0.05 were considered statistically significant. All analyses were 185 conducted using SAS/STAT version 9.4 (SAS Institute Inc., Cary N.C. USA). 186

187

# 189 **Results**

#### 190 **Demographics**

Over the study period, 65 patients with a clinical diagnosis of PWS were screened. Of 191 these, 14 underwent randomization. Participant disposition in the study is shown in the CONSORT 192 flow diagram (Fig 1). The study population included 11 males and 3 females, aged between 6 to 193 35 years, carrying genetically confirmed diagnoses of PWS. Of these subjects, 78.5% were 194 Caucasian, and 7% were Asian. Table 1 reviews the demographics of the participants. Subtype 195 196 distribution showed that 29% of the subjects carried paternal deletion and 43% had maternal uniparental disomy. Further, the submitted test reports did not distinguish subtype in 28% of the 197 participants. 198

199

200 Fig 1. CONSORT flow diagram. Participant disposition in double-blind, randomized placebo-

201 controlled trial for GXR (guanfacine-extended release)

202

		Placebo (n=7)	Guanfacine XR (n=7)	P-value
Age (years)		8 (8-16)	10 (7 - 10)	0.383
Sex	Female	1 (14.3%)	2 (28.6%)	4 000
	Male	6 (85.7%)	5 (71.4%)	1.000
Ethnicity	Hispanic or Latino	1 (14.3%)	2 (28.6%)	
	Not Hispanic or Latino	6 (85.7%)	5 (71.4%)	1.000
Race	Missing	1 (14.3%)	0 (0%)	
	Asian	0 (0%)	1 (14.3%)	
	Middle Eastern	0 (0%)	1 (14.3%)	1.000
	White	6 (85.7%)	5 (71.4%)	
Blood	Systolic	123 (103 - 126)	103 (101 - 121)	0.383
<b>Pressure</b> (mmHg)	Diastolic	77 (68 - 81)	72 (60 - 74)	0.535
Heart Rate (bpm)		82 (63 - 101)	87 (74 - 101)	0.5
ECG (QTcF)		397 (384 - 413)	398 (391 - 413)	0.805
Height (cm)		147.32 (132.5 - 152)	136 (124.8 - 152.4)	0.456
Weight (kg)		65.8 (33.2 - 77.6)	48.2 (29.8 - 66.8)	0.318
BMI (Body Mass Index)		28.5 (18.7 - 35.2)	23.6 (18.1 - 30.7)	0.456

#### 204 Table 1. Baseline Demographics and Clinical Characteristics of Study Participants.

All numeric variables were summarized with median and IQR and compared across groups with a

*Wilcoxon Rank Sum Test.* All categorical variables were summarized with frequency and percentage and
 compared across groups with a *Fisher Exact Test.*

208

### 209 Patient Baseline Characteristics

As seen in Table 2, there were no differences among the groups at baseline for any

211 measures, including severity of illness as measured by the CGI-S.

212

Outcome Measures	Placebo (n=7)	GXR (n=7)	P-value
ABC	58 (45 - 67)	48 (24 - 70)	0.620
ABC - Subscale I, Irritability	21 (15 - 23)	15 (6 - 26)	0.710
ABC - Subscale II, Social Withdrawal	16 (5 - 20)	11 (2 - 24)	0.456
ABC - Subscale III, Stereotypic Behavior	2 (0 - 6)	0 (0 - 2)	0.383
ABC - Subscale IV, Hyperactivity/Noncompliance	16 (12 - 24)	9 (6 - 22)	0.209
ABC - Subscale V, Inappropriate Speech	5 (4 - 8)	7 (4 - 9)	0.710
CGI-S	6 (5 - 6)	5 (5 - 6)	0.535
ESS	10 (6 - 13)	7 (1 - 8)	0.383
HQ-CT	14 (8 - 16)	14 (6 - 25)	0.805
MOAS (total weighted score)	11 (11 - 17)	13 (9 - 17)	1.000
MOAS - Verbal Aggression Subscale	2 (1 - 2)	2 (2 - 2)	0.805
MOAS - Aggression Against Property Subscale	2 (2 - 4)	2 (0 - 4)	0.620
MOAS - Autoaggression Subscale	3 (3 - 3)	3 (3 - 6)	0.259
MOAS - Physical Aggression Subscale	4 (3 - 8)	8 (0 - 8)	0.902
SIT - Number Index Score	1 (1 - 2)	2 (1 - 2)	0.620
SIT - Severity Index Score	2 (1 - 5)	2 (1 - 3)	1.000

#### 214 Table 2. Subject Behavioral Measure Scores at Index Visit.

215 ABC, Aberrant Behavior Checklist; CGI-S, Clinical Global Impression – Severity scale; ESS, Epworth

Sleepiness; *HQ-CT*, Hyperphagia Questionnaire for use in PWS clinical trials; *MOAS*, Modified Overt
 Aggression Scale; *SIT*, Self-Injury Trauma scale.

218 All numeric variables were summarized with median and IQR and compared across groups with a

219 Wilcoxon Rank Sum Test.

220

#### 221 **Response to GXR**

In repeated measures linear regression models, using GEE and an unstructured correlation

matrix, there was a decrease in the Aberrant Behavior Checklist score of 9.962 points (95% CI: 19

- 0.8), p=0.03, in subjects receiving GXR treatment as seen in Table 3. A decrease in ABC subscale

- IV (Hyperactivity) of 5.27 points (95% CI: 1.23 9.30), p=0.01, was also observed in this group.
- 226 While on GXR, subjects demonstrated a reduction in aggressive behaviors as reflected in the
- decrease in MOAS score of 3.65 points (95% CI: 0.50 6.79), p=0.02. The number of skin-picking
- lesions also decreased in response to GXR, as indicated by the SIT scale scores in the treatment

- arm; however, this decrease was not significant in comparison to that observed in the placebo arm.
- 230 There was a highly significant improvement in the overall behavioral symptoms of participants on
- GXR, as reflected by the lower scores in the psychiatrist-rated CGI-I scales [1.25 points, (95% CI:
- 0.47 2.04), p=0.002]. There were no other statistical differences observed in outcome measures.
- Fig 2 demonstrates a schematic forest plot of the different effect sizes across measures.
- 234

#### **Table 3. GEE Models for Additional Outcomes and Scales.**

	β	95% CI		P-value
Outcome Measures		LCL	UCL	
ABC	-9.962	-19.136	-0.788	0.033
ABC - Subscale I, Irritability	-1.253	-5.08	2.574	0.521
ABC - Subscale II, Social Withdrawal	0.252	-1.918	2.421	0.821
ABC - Subscale III, Stereotypic Behavior	-0.447	-1.171	0.277	0.226
ABC - Subscale IV, <i>Hyperactivity/Noncompliance</i>	-5.266	-9.298	-1.233	0.01
ABC - Subscale V, Inappropriate Speech	-0.637	-1.398	0.123	0.10
CGI-S	-0.304	-0.938	0.329	0.347
CGI-I	-1.25	-2.036	-0.465	0.002
ESS	0.425	-2.684	3.533	0.789
HQ-CT	-4.94	-15.45	5.57	0.357
MOAS (total weighted score)	-3.645	-6.794	-0.496	0.023
SIT - Number Index Score	-0.639	-1.374	0.096	0.089
SIT - Severity Index Score	-1.121	-3.611	1.368	0.377

236 **ABC**, Aberrant Behavior Checklist; **CGI-S**, Clinical Global Impression – Severity scale; **CGI-I**; Clinical

237 Global Impression - Improvement scale; ESS, Epworth Sleepiness; HQ-CT, Hyperphagia Questionnaire

for use in PWS clinical trials; *MOAS*, Modified Overt Aggression Scale; *SIT*, Self-Injury Trauma scale.

239

240 Fig 2. Forest plot. A schematic of the different effect sizes across measures in the two study

241 groups based on GEE Models (Generalized Estimating Equations)

# 243 Side Effects and Tolerability

244	There were no serious adverse events (SAEs) reported by subjects in either of the study
245	groups. However, subjects on GXR were more likely to experience fatigue 29% vs 93%, $p = 0.012$ .
246	Table 4 shows all the treatment-emergent adverse events observed among trial subjects in GXR
247	and placebo groups. There were no other differences in the rate of adverse events amongst the
248	groups.
249	There were no GXR-related clinically meaningful changes in ECG and QTc-related
250	parameters. No significant changes in vital signs, or lab values were observed between the groups.
251	The average stable dose of GXR at time of completion of the study was 2.75 mg daily.
252	

Adverse Event	Placebo (n=7)	GXR (n=14)	P-value
Anxiety	1 (14%)	2 (14%)	1.000
Depressed	1 (14%)	5 (36%)	0.615
Dry Mouth	1 (14%)	1 (7%)	0.490
Increased Appetite	2 (29%)	3 (21%)	0.583
Irritable Aggression	1 (14%)	5 (36%)	0.615
Constipation	0 (0%)	1 (7%)	1.000
Fatigue	2 (29%)	13 (93%)	0.012
Enuresis	1 (14%)	3 (21%)	1.000
Excessive Talking	0 (0%)	2 (14%)	1.000
Skin Picking	0 (0%)	2 (14%)	1.000
Diarrhea	2 (29%)	1 (7%)	0.172
Mild Sleep Awakening	0 (0%)	3 (21%)	0.522
Dizziness	0 (0%)	1 (7%)	1.000
Decreased Appetite	0 (0%)	1 (7%)	1.000
Difficult Swallowing	0 (0%)	1 (7%)	1.000
Headache	1 (14%)	1 (7%)	0.490
Increased Energy	0 (0%)	1 (7%)	1.000

#### 254 Table 4. Incidence of Adverse Events

Adverse events are expressed as frequencies (and percentage) of participants for each treatment-emergent

adverse event and compared across groups with a *Fisher Exact Test*.

257

258

# 259 **Discussion**

260	Behavioral and psychiatric symptoms are common in the PWS patient population.
261	Individuals with PWS may exhibit impulsive behavior, which can impede daily functioning and
262	lead to risky behavior. <sup>6, 7, 32</sup> Furthermore, patients can exhibit aggression and temper tantrums,
263	which leads to significant caregiver burden. <sup>5, 33</sup> Skin-picking is another behavioral symptom
264	commonly seen in this patient population, which may get complicated with infections and scarring

at the site of damage. <sup>19</sup> The overall burden of illness over the lifetime of an individual with PWS
is compounded by these behavioral problems.

Currently, the commonly used pharmacological treatment options for behavioral 267 management in individuals with PWS are SRIs, stimulants, and atypical antipsychotics. Their use 268 in PWS is widespread despite the lack of empirical placebo-controlled studies to demonstrate 269 efficacy. These medications are associated with significant risks including weight gain for 270 271 antipsychotics, psychosis for SRIs, and increased skin excoriation with stimulants. With the exception of NAC, options are limited for the treatment of skin-picking behavior. <sup>19, 20, 21, 1, 34</sup> 272 Therefore, investigating relatively safe medication options that can effectively manage several 273 274 impairing behavioral symptoms seen in PWS is warranted to positively impact the lives of patients and to reduce caregiver fatigue. 275

This randomized double-blind, placebo-controlled, fixed-flexible dose clinical trial with 276 277 open-label continuation, was designed to explore the efficacy, safety, and tolerability of guanfacine extended release in the management of aggression and self-injurious behavior (skin picking) in 278 individuals with PWS. The results of this study demonstrate that GXR ameliorates overall 279 280 behavioral disturbances as measured by the ABC scale. GXR was particularly effective against hyperactivity in PWS. This finding is expected since GXR has established evidence for the 281 treatment of ADHD in the general population. 35, 36 Additionally, GXR led to a significant 282 283 reduction in aggressive behavior as measured by the MOAS. Our study also showed a positive response to GXR in terms of skin picking, with a reduction in the number of lesions in the treatment 284 285 group, although it was not statistically significant as compared to that in the placebo group.

Notably, subjects on GXR showed a significant improvement in their overall presentation asmeasured by the CGI-I scale.

GXR was generally well tolerated with the most commonly reported side effect being 288 fatigue, commensurate with the findings in the general population.<sup>37</sup> It is important to note that 289 despite this, the overall level of daytime sleepiness as measured by the ESS did not show any 290 statistical difference from placebo. This finding is of particular salience given the high rates of 291 daytime sleepiness experienced in this population. <sup>38</sup> There were no serious adverse events 292 reported in the GXR group. Another key factor to consider in this study is that, none of the subjects 293 exposed to GXR experienced weight gain. There was no difference noted between the GXR and 294 295 placebo groups with respect to ECG changes, blood pressure, or heart rate.

Several outcomes trended towards a positive response but failed to reach a statistical
significance level. In particular, a positive signal was observed for hyperphagia and skin picking.
These need to be confirmed in future studies with a larger sample size.

Individuals with PWS suffer from growth hormone (GH) deficiency, which contributes to 299 300 the short stature and the central obesity. GH replacement therapy has shown beneficial effects in aiding linear growth, and restoring normal body composition, bone density, as well as lipid profile 301 values in individuals with PWS.<sup>39 40</sup> At the time of this writing, GH is the only medication that 302 has an FDA approved indication for the management of PWS. <sup>41</sup> Clonidine is an  $\alpha$ 2-adrenoceptor 303 agonist similar to GXR, and both medications have been shown to increase GH levels in a dose-304 dependent manner. However, GXR is less sedating compared to clonidine and may be a better 305 alternative in this setting. <sup>42</sup> Although not measured in the current study, the possible physical 306 benefits of increased GH could indicate an additional advantage of GXR in comparison to other 307

medications used for the behavioral management of individuals with PWS. This could be furtherelucidated in prospective trials.

310

#### 311 **Limitations**

The multiple limitations of this study need to be highlighted. Although there were no gender 312 313 differences between the active and placebo arms, the majority of patients enrolled were male. A larger study could reduce the possibility of there being a gender based moderating effect on the 314 results. A larger sample size would also allow stratification of the results by PWS genotype. 315 Similarly, the participants were predominantly Caucasian hence limiting generalizability of 316 findings. The study was conducted at a single site, limiting the diversity in participants that can be 317 achieved from a multicenter study. It is challenging to establish external validity in a single-site 318 study, due to limitations of accounting for the variance in environmental and practitioner-based 319 factors. Another factor that must be considered is the relatively high prevalence of ADHD and 320 autism in PWS.<sup>6</sup> Therefore, there is a possibility that the observed effects may be moderated by 321 these co-existing conditions. 322

Despite these challenges to the study, the results of this clinical trial, along with prior knowledge of the side effects posed by the alternatives available to practitioners, suggests that GXR should be the first line treatment for behavioral problems, specifically aggression, irritability, and hyperactivity in individuals with PWS.

328

# 329 **Conclusions**

This randomized, fixed-flexible dose placebo-controlled clinical trial, with open label 330 extension, aimed to provide a supporting framework for the utilization of GXR in the management 331 of behavioral symptoms comorbid with PWS. The assessed symptoms included aggression, 332 irritability, inattention/hyperactivity, and skin-picking. GXR treatment leads to global 333 improvement in symptoms, particularly those related to behavioral disturbance in persons with 334 PWS. Specifically, GXR reduces aggression and hyperactivity in this population. Additionally, 335 there are possible beneficial effects on skin picking behavior. The most commonly reported side 336 337 effect was fatigue, but overall daytime sleepiness was not worse than placebo. There were no serious adverse effects reported. GXR did not lead to any change in weight, heart rate, blood 338 pressure, or cardiac rhythm, as compared to placebo. The results of this clinical trial suggests that 339 340 GXR is an effective and relatively safe treatment modality for behavioral problems in patients with PWS. 341

## 342 Clinical Significance

Individuals with PWS often present with challenging behavioral disturbances such as aggression/agitation, skin-picking, and ADHD symptoms like impulsivity and inattention. Current management strategies for behavioral disturbances in PWS patients show limited efficacy and can have significant side effects. Although other studies have been conducted to assess treatment options against hyperphagia, this is the first randomized placebo-controlled trial examining the efficacy of a psychotropic medication against the behavioral manifestations of PWS. This

randomized placebo-controlled clinical trial demonstrated that GXR is effective in the management of behavioral disturbances in PWS while being well tolerated. The authors recommend that GXR be considered as a first line treatment strategy for the management of behavioral problems, especially aggression and hyperactivity, associated with PWS.

353

354

## 355 Supporting Information

356 S1 Checklist. CONSORT Checklist

357

358

## 359 Acknowledgments

The authors would like to thank our hospital pharmacists Jason Brady and Rina Evans for their invaluable contribution. We would also like to thank our clinical research coordinators Otuwe Anya and Hasan Mustafic, without whom this study would not have been possible.

363

364

365 **References** 

<sup>1</sup> Miller JL, Tamura R, Butler MG, Kimonis V, Sulsona C, Gold JA et al. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study. Am J Med Genet A. 2017;173A:1243-50.

<sup>2</sup> Butler MG. Prader-Willi Syndrome: Obesity due to Genomic Imprinting. Curr Genomics. 2011;12:204-15.

<sup>3</sup> Ogura K, Shinohara M, Kousaku O, Mori E. Frontal behavioral syndromes in Prader-Willi syndrome. Brain Dev. 2008;30:469-76.

<sup>4</sup> Arron K, Oliver C, Moss J, Berg K, Burbidge C. The prevalence and phenomenology of selfinjurious and aggressive behaviour in genetic syndromes. J Intellect Disabil Res. 2011;55:109-20.

<sup>5</sup> Tunnicliffe P, Woodcock K, Bull L, Oliver C, Penhallow J. Temper outbursts in Prader-Willi syndrome: causes, behavioral and emotional sequence and responses by carers. J Intellect Disabil Res. 2014;58:134-50.

<sup>6</sup> Ogata H, Ihara H, Murakami N, Gito M, Kido Y, Nagai T. Autism spectrum disorders and hyperactive/impulsive behaviors in Japanese patients with Prader-Willi syndrome: a comparison between maternal uniparental disomy and deletion cases. Am J Med Genet A. 2014;164A:2180-6.

<sup>7</sup> Wigren M, Hansen S. ADHD symptoms and insistence on sameness in Prader-Willi syndrome. J Intellect Disabil Res. 2005;49:449-56.

<sup>8</sup> Greaves N, Prince E, Evans DW, Charman T. Repetitive and ritualistic behavior in children with Prader-Willi syndrome and children with autisum. J Intellect Disabil Res. 2006;50:92-100.

<sup>9</sup> Banga A, Connor DF. Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome. J Child Adolesc Psychopharmacol. 2012;22:396–8.

<sup>10</sup> Bonnot O, Cohen D, Thuilleaux D, Consoli A, Cabal S, Tauber M. Psychotropic treatments in Prader Willi syndrome: a critical review of published literature. Eur J Pediatr. 2016;175:9-18.

<sup>11</sup> Matesevac L, PATH for PWS Study 2021 Update: A Non-Interventional, Observational, Natural History Study of Serious Medical Events in Prader-Willi Syndrome. Presented in the PWSA-USA Medical & Scientific Conference 2021, Virtual. https://www.pwsausa.org/2021national-convention-session-recordings/

<sup>12</sup> Kohn Y, Weizman A, Apter A. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord. 2001;30:1137.

<sup>13</sup> Kraemer S, Minarzyk A, Forst T, Kopf D, Hundemer HP. Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics—results from a German observational study. BMC Psychiatry. 2011;11:173.

<sup>14</sup> Hellings JA. Self-injurious behavior and serotonin in Prader-Willi syndrome.Psychopharmacol Bull. 1994;20:245-50.

<sup>15</sup> Warnock JK, Kestenbaum T. Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Two case reports. Arch Dermatol. 1992;128:1623-5.

<sup>16</sup> Herguner S, Mukaddes NM. Psychosis associated with fluoxetine in Prader-Willi syndrome.J Am Acad Child Adolesc Psychiatry. 2007;46:944-45.

<sup>17</sup> Dennison EA, Raidoo BM, Cruz R, Raidoo D. A case of high-dose venlafaxine-related psychosis. J Clin Psychopharmacol. 2013;33:134–6.

<sup>18</sup> Kara T, Akaltun I. Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder: Possible Mechanisms. Clin Neuropharmacol. 2018;41:28-30.

<sup>19</sup> Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A. 2014;164A:421-4.

<sup>20</sup> Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011;6:47.

<sup>21</sup> Kuppens RJ, Donze SH, Hokken-Koelega AC. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial. Clin Endocrinol (Oxf). 2016;85:979-87.

<sup>22</sup> Website: "Drugs@FDA: FDA Approved Drug Products." Accessdata.fda.gov,
 <u>www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=20088</u>
 <u>1</u>. (Access date: July 09, 2018)

<sup>23</sup> Cruz MP. Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder. P T. 2010;35:448-51.

<sup>24</sup> Schulz KP, Clerkin SM, Fan J, Halperin JM, Newcorn JH. Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control. Psychopharmacology (Berl). 2013;226:261-71.

<sup>25</sup> Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60:42-51.

<sup>26</sup> Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L et al. Research Units on Pediatric Psychopharmacology Autism Network. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. Am J Psychiatry. 2015;172:1197-206.

<sup>27</sup> Davis NO, Kollins SH. Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics. 2012;9:518-30.

<sup>28</sup> Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24:1861-72.

<sup>29</sup> Singh D, Kadakia N, Pinkhasov A. Significant reduction of aggression with guanfacine extended release in an adolescent with Prader-Willi syndrome. J Child Adolesc Psychopharmacol. 2015;25:376-7.

<sup>30</sup> Singh D, Wakimoto Y, Filangieri C, Pinkhasov A, Angulo M. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study. J Child Adolesc Psychopharmacol. 2019;29:313-7.

<sup>31</sup> Soni S, Whittington J, Holland AJ, Webb T, Maina E, Boer H, et al. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: Implications for management and treatment. J Intellect Disabil Res. 2007;51:32–42.

<sup>32</sup> Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385:2190-6.

<sup>33</sup> Mazaheri MM, Rae-Seebach RD, Preston HE, Schmidt M, Kountz-Edwards S, Field N et al. The impact of Prader-Willi syndrome on the family's quality of life and caregiving, and the unaffected siblings' psychosocial adjustment. J Intellect Disabil Res. 2013;57:861–73. <sup>34</sup> Logan SL, Carpenter L, Leslie RS, Garrett-Mayer E, Hunt KJ, Charles J et al. Aberrant Behaviors and Co-occurring Conditions as Predictors of Psychotropic Polypharmacy among Children with Autism Spectrum Disorders. J Child Adolesc Psychopharmacol. 2015;25:323– 36.

<sup>35</sup> Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57:717-28.

<sup>36</sup> Butterfield ME, Saal J, Young B, Young JL. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. Psychiatry Res. 2016;236:136-41.

<sup>37</sup> Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:916-25.e2.

<sup>38</sup> Duis J, Pullen LC, Picone M, Friedman N, Hawkins S, Sannar E et al. Diagnosis and management of sleep disorders in Prader-Willi syndrome. J Clin Sleep Med. 2022;18:1687-96.

<sup>39</sup> Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hubner C, Hokken-Koelega AC. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of


Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database. J Clin Endocrinol Metab. 2017;102:1702–11.

<sup>40</sup> Sipila I, Sintonen H, Hietanen H, Apajasalo M, Alanne S, Viita A-M, et al. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. Acta Paediatr. 2010;99:1712–8.

<sup>41</sup> Singh D, Miller JL, Wassman ER, Butler MG, Foley Shenk A, Converse M et al. The Arduous Path to Drug Approval for the Management of Prader-Willi Syndrome: A Historical Perspective and Call to Action. Int J Mol Sci. 2023;24:11574.


<sup>42</sup> Balldin J, Berggren U, Eriksson E, Lindstedt G, Sundkler A. Guanfacine as an alpha-2agonist inducer of growth hormone secretion--a comparison with clonidine. Psychoneuroendocrinology. 1993;18:45–55.

## Figure 1. CONSORT Flow Diagram



# Figure 1

### Figure 2. Forest Plot based on GEE Models



Model: Random-effects model

# Figure 2